- 50+ clinical sites in Germany, Poland, Bulgaria, Romania, India
- 100+ investigators in diabetes research
- Completion of two clinical programs with recombinant Insulins
Diabetes type 1 and type 2
- six phase III trials in 2100 type 1 and type 2 diabetes patients
- immunogenicity trials
- clamp trials
Diabetes patients with foot ulcer
- Phase II trial in 45 patients